Loading
TNFAIP3 (Tumour necrosis factor alpha-induced protein 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Skin cancer and 2 more.
Ubiquitin-editing enzyme that contains both ubiquitin ligase and deubiquitinase activities. Involved in immune and inflammatory responses signalled by cytokines, such as TNF and IL-1 beta, or pathogens via Toll-like receptors (TLRs) through terminating NF-kappa-B activity. Essential component of a ubiquitin-editing protein complex, comprising also RNF11, ITCH and TAX1BP1, that ensures the transient nature of inflammatory signalling pathways.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.62 (direct and indirect evidence; datatypes literature 0.98, animal model 0.53, genetic association 0.06, somatic mutation 0.95). IntOGen calls it a driver in 3 cohorts (0 activating, 3 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS.
In plain words · TNFAIP3 (Tumour necrosis factor alpha-induced protein 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Skin cancer and 2 more.
TNFAIP3 (Tumour necrosis factor alpha-induced protein 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Skin cancer and 2 more.
Ubiquitin-editing enzyme that contains both ubiquitin ligase and deubiquitinase activities.
No product in this corpus aims at TNFAIP3 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it a tumour suppressor (IntOGen finds it knocked out more often than chance); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA TNFAIP3: RNA tissue enhanced (bone marrow 394 nTPM, urinary bladder 146 nTPM); high antibody staining in 2 normal tissues. Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lymphoma, Leukaemia, Skin cancer (all types)); Open Targets associates it with 1 specific cancer type at or above 0.5 (diffuse large B-cell lymphoma). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P21580; CIViC gene TNFAIP3; IntOGen TNFAIP3; Human Protein Atlas TNFAIP3 tissue; Open Targets ENSG00000118503 associations
First described 1990. Earliest sequence paper UniProt cites for the protein: Opipari A.W. Jr. et al, J. Biol. Chem, 1990, "The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type of zinc finger protein". Source.
Sources: HGNC HGNC:11896 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P21580 (protein name, function text, keywords and locations (REST API)); CIViC gene TNFAIP3 (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000118503 (association with cancer (MONDO_0004992) 0.62; per-cancer scores at or above 0.5: diffuse large B-cell lymphoma 0.65, non-Hodgkin lymphoma 0.69, skin cancer 0.53, leukaemia 0.54, marginal zone lymphoma 0.52 (GraphQL API, CC0)); IntOGen TNFAIP3 (driver in 3 cohorts (Act 0, LoF 3); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Ubiquitin-editing enzyme that contains both ubiquitin ligase and deubiquitinase activities. Involved in immune and inflammatory responses signalled by cytokines, such as TNF and IL-1 beta, or pathogens via Toll-like receptors (TLRs) through terminating NF-kappa-B activity. Essential component of a ubiquitin-editing protein complex, comprising also RNF11, ITCH and TAX1BP1, that ensures the transient nature of inflammatory signalling pathways. In cooperation with TAX1BP1 promotes disassembly of E2-E3 ubiquitin protein ligase complexes in IL-1R and TNFR-1 pathways; affected are at least E3 ligases TRAF6, TRAF2 and BIRC2, and E2 ubiquitin-conjugating enzymes UBE2N and UBE2D3. In cooperation with TAX1BP1 promotes ubiquitination of UBE2N and proteasomal degradation of UBE2N and UBE2D3. Upon TNF stimulation, deubiquitinates 'Lys-63'-polyubiquitin chains on RIPK1 and catalyses the formation of 'Lys-48'-polyubiquitin chains. Location: Cytoplasm; Nucleus; Lysosome (UniProt). Locus 6q23.3 (HGNC).
RNA: tissue enhanced (bone marrow 394 nTPM, urinary bladder 146 nTPM), detected in all normal tissues.
Medium: Adipose tissue, Adrenal gland, Appendix, Bone marrow, Bronchus, Caudate, Cerebellum, Cerebral cortex.
No cancer stained high; medium in breast cancer, cervical cancer, colorectal cancer, endometrial cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"TNFAIP3" OR ABSTRACT:"TNFAIP3" OR TITLE:"TNF alpha induced protein 3" OR ABSTRACT:"TNF alpha induced protein 3" OR TITLE:"Tumor necrosis factor alpha-induced protein 3" OR ABSTRACT:"Tumor necrosis factor alpha-induced protein 3" OR TITLE:"A20" OR ABSTRACT:"A20" OR TITLE:"OTUD7C" OR ABSTRACT:"OTUD7C") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TNFAIP3, not a curated reading list.
Shares Microbiome-tumour interactions, Inflammation & NF-κB, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Marginal zone lymphoma.
Shares Microbiome-tumour interactions, Inflammation & NF-κB, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Marginal zone lymphoma.
Shares Microbiome-tumour interactions, Inflammation & NF-κB, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Marginal zone lymphoma.
Shares Marginal zone lymphoma, Leukaemia (all types), Skin cancer (all types), CIViC.
Shares Leukaemia (all types), Skin cancer (all types), CIViC, IntOGen.
Shares Leukaemia (all types), Skin cancer (all types), CIViC, IntOGen.
Shares Leukaemia (all types), Skin cancer (all types), CIViC, IntOGen.
Shares Leukaemia (all types), Skin cancer (all types), CIViC, IntOGen.